Guizhou Yibai Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 600594.SS

Guizhou Yibai Pharmaceutical Co., Ltd. Receivables for the year ending December 31, 2023: USD 0.00

Guizhou Yibai Pharmaceutical Co., Ltd. Receivables is USD 0.00 for the year ending December 31, 2023, a -100.00% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Guizhou Yibai Pharmaceutical Co., Ltd. Receivables for the year ending December 31, 2022 was USD 104.66 M, a -4.82% change year over year.
Guizhou Yibai Pharmaceutical Co., Ltd. Receivables for the year ending December 31, 2021 was USD 109.95 M, a -31.98% change year over year.
Guizhou Yibai Pharmaceutical Co., Ltd. Receivables for the year ending December 31, 2020 was USD 161.66 M, a 8.26% change year over year.
Guizhou Yibai Pharmaceutical Co., Ltd. Receivables for the year ending December 31, 2019 was USD 149.32 M, a -6.56% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Shanghai Stock Exchange: 600594.SS

Guizhou Yibai Pharmaceutical Co., Ltd.

CEO	Ms. Ya Qi Dou
IPO Date	March 23, 2004
Location	China
Headquarters	No. 220-1, Baiyun Avenue
Employees	5,509
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatism, digestive system, pediatric, gynecological, anti-infection, anti-inflammatory, analgesic, and other diseases. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years